Matt Lanchantin is the Head of Corporate Development at Syntis Bio, a biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare metabolic diseases. He oversees capital sourcing, strategic partnerships, and portfolio development, with a focus on identifying and advancing novel therapeutic and/or drug delivery applications for the company’s SYNT™ technology platform. Matt is also a co-founder of Nucleate, a global nonprofit dedicated to empowering the next generation of biotech leaders and entrepreneurs. He began his career at the bench and has since held research and strategy roles across multiple life sciences companies, leading licensing and M&A transactions spanning oncology, cardiovascular, and metabolic diseases. Matt holds an MBA from the MIT Sloan School of Management and a BS in Chemical and Biological Engineering from Tufts University.

‍